Alitretinoin – its use in intractable hand eczema and other potential indications by Petersen, Bibi & Jemec, Gregor BE
© 2009 Petersen and Jemec, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Drug Design, Development and Therapy 2009:3 51–57 51
REVIEW
Alitretinoin – its use in intractable hand eczema 
and other potential indications
Bibi Petersen
Gregor BE Jemec
Dept of dermatology, Health Sciences 
faculty, University of Copenhagen, 
Roskilde Hospital, Denmark
Correspondence: Bibi Petersen
Dept of dermatology, Health Sciences 
faculty, University of Copenhagen, 
Roskilde Hospital, Denmark
Fax +45 47 32 26 98
Email bibp@regionsjaelland.dk
Abstract: Chronic hand eczema is a signiﬁ  cant cause of morbidity. A number of treatments are 
traditionally used, and often useful, but in spite of this a sizeable group of patients develop chronic 
recalcitrant hand eczema. Retinoids are known to inﬂ  uence keratinization and inﬂ  ammation, and 
acitretin has shown some effect in the treatment of chronic hand eczema. Alitretinoin (9-cis-retinoic 
acid) is a panagonist retinoid binding to all six known retinoid receptors (RAR-α, -β, -γ and 
RXR-α, -β, -γ). Several studies have been carried out with this new drug, and it has been shown 
to be effective in 28% to 89% of patients with previously intractable hand eczema. In addition, 
alitretinoin appears to have some potential in the treatment of AIDS-related Kaposi sarcoma. 
Attempts to use the drug in secondary prophylaxis has shown some promise in former tobacco 
smokers, whereas no effect was seen in patients with cervical intraepithelial neoplasia. Currently, 
the primary therapeutic potential of alitretinoin appears to be the treatment of chronic recalcitrant 
hand eczema, which also forms a large and hitherto neglected group of patients.
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Chronic hand dermatitis (CHD) is invalidating socially and occupationally, with an 
increased risk of prolonged sick leave and unemployment.1
CHD is characterized by erythema, vesicles, papules, edema, scaling, ﬁ  ssures, 
hyperkeratosis, and symptoms of itch and pain, and is classiﬁ  ed into the following subgroups 
based on etiology and morphology: irritant contact dermatitis, allergic contact dermatitis, 
atopic dermatitis, hyperkeratotic eczema, nummular hand eczema, endogen eczema and 
pompholyx (dyshidrotic eczema), with no existing agreement of classiﬁ  cation.1
For patients with severe CHD the treatment options have hitherto been limited. 
Besides the usually advise of avoiding allergens and irritants, treatment with emollients, 
corticosteroids, UV-irradiation, ionizing radiation and immunosuppressants have been 
used with varying effect. A systemic immunosuppressive treatment is a possibility for 
shorter periods, but is not suitable for long-term treatment, and therefore an effective 
alternative is needed. Previous studies have suggested that retinoids may provide a 
useful non-immunosuppressive alternative treatment. Retinoids are known to have 
a normalizing effect on cell differentiation, to be antiproliferative and to regulate 
cell-apoptosis. The present retinoid that is indicated in the treatment of chronic hand 
eczema is acitretin, although the effect has been limited.
The new pan-retinoid-receptor agonist 9-cis-retinoid acid has been experimen-
tally used in the treatment of different diseases. Alitretinoin is a panagonist retinoid, 
which is capable of binding to all six known retinoid receptors (RAR-α, -β, -γ and 
RXR-α, -β, -γ), in contrast to tretinoin that primarily binds to RAR-α, acitretin that 
activates but does not bind to RARs and 13-cis-retinoid acid that shows low afﬁ  nity 
for RARs.2 Therefore alitretinoin is expected to be effective in a different spectrum of 
diseases. Good results have also been shown with alitretinoin in the treatment for CHD, Drug Design, Development and Therapy 2009:3 52
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Kaposi’s sarcoma (KS) and a moderate effect in the therapy 
of speciﬁ  c cancers has been demonstrated.3–15
The aim of this work was to review recent advances in the 
treatment of CHD synonymous with chronic hand eczema, 
and to review previous trials of the retinoid alitretinoin 
(9 cis-retinoic acid (RA)) in the treatment of this and other 
diseases.
Chronic hand dermatitis 
and treatment
In the therapy of CHD the ﬁ  rst step is skin protection and 
prophylaxis; using gloves, avoiding irritants and allergens 
and using emollients. Topical application with corticosteroid 
creams and ointments is the mainstay in treatment of CHD; 
alternatively or in addition to this, topical immunomodulators, 
coal tar, ultraviolet (UV) light and ionizing radiation are used 
topically. Treatment of CHD with corticosteroids is well 
documented.16 Because many patients with CHD often do not 
respond adequately to topical treatment, it is frequently neces-
sary to change to a systemic immunosuppressive treatment.
The effect of topical calcineurin inhibitors (TCIs) has 
been evaluated in two studies. An open prospective study 
with 29 patients showed over 50% reduction in 59% of 
patients after 4 weeks of treatment with tacrolimus ointment 
(Protopic® 0.1%) and 44% were cleared of hand eczema at 
the ﬁ  nal visit.17 Another small randomized study evaluated 
the effect of tacrolimus 0.1% versus mometasone furuate 
0.1% in the treatment of dyshidrotic eczema on palms and 
soles. Tacrolimus was found equally effective to mometasone 
furuate in chronic dyshidrotic eczema of the hands, but no 
effect was seen in plantar eczema.18
The effect of UV-light therapy has been investigated, 
and both irradiation with UVA-1 and UVB have been found 
effective.19,20
Several studies have documented the effect of local 
PUVA treatment.21,22 Methotrexate has been described as an 
effective treatment and steroid-sparing agent in recalcitrant 
palmoplantar pompholyx.23
A good effect of cyclosporine has been shown in a 
study including patients with eczematous diseases including 
CHD and a possible long-term remission after withdrawal 
of cyclosporine was suggested.24 Another study supported 
these results.25
Chronic hand dermatitis 
and retinoids
Retinoids exert their effect by binding to speciﬁ  c nuclear 
receptors and thereby regulate cell growth and cellular 
proliferation, differentiation and apoptosis. This effect is a 
class effect, but each retinoid has a higher afﬁ  nity for speciﬁ  c 
receptors. Retinoid receptors are divided into two groups: 
RAR-α,β,γ and RXR-α,β,γ.
In the skin the predominant retinoid receptor is the 
RAR-γ/RXR-α heterodimer.26
Topical treatment with bexarotene gel for 22 weeks 
has been investigated in an open label randomized (into 
3 treatment arms) study including 55 patients with CHD. 
According to the physician assessment (PA) bexarotene gel 
(BG) was comparative in effect to bexarotene gel combined 
with topical mometasone furoate ointment 0.1% (BG + MF) 
and superior to BG in combination with topical hydrocorti-
sone ointment 1% (BG + HC). An improvement of over 50% 
was seen in 79% of the BG arm, 77% in the BG + MF arm 
and 50% of the BG + HC arm. These results were supported 
by the secondary end-points: The Eczema Area and Severity 
Index (EASI) and The Hand EASI (HEASI).27
In a single-blinded randomized study treatment of 
hyperkeratotic hand eczema with 30 mg of acitretin daily or 
placebo, acitretin was found to be statistically signiﬁ  cantly 
more effective than placebo. There was an overall 51% reduc-
tion in clinical symptoms after 4 weeks in the acitretin group 
compared with a 9% reduction in the placebo group.28
Chronic hand dermatitis 
and alitretinoin
Alitretinoin (9-cis RA) is known to be a panagonist retinoid 
with high afﬁ  nity to all six retinoid receptors, in contrast 
to other known retinoids which target mainly RAR-
receptors.2,26 Therefore it is expected to exert its effect 
in a different way than previously used retinoids such as 
acitretin.
In 1999 alitretinoin was described as an effective 
treatment for CHD after an open-label study with oral 
9-cis-retinoic acid. It included 38 patients with the following 
diagnoses: pompholyx, hyperkeratotic eczema, ﬁ  ngertip 
eczema and discoid eczema, all with unsatisfactory response 
to previous treatments. All patients were given a once daily 
oral dose of 20 or 40 mg alitretinoin, in a mean duration of 
2.3 months (range 1–5 months). Therapeutic response (TR) 
was conducted with a 4-point scale (0 = none, 1 = slight, 
2 = moderate, 3 = marked, 4 = severe) recorded for each of 
the lesions and symptoms: erythema, papules, desquamation, 
hyperkeratosis, rhagades and pruritus; thereafter a reduction 
was evaluated in percent. A reduction in total lesion 
symptom score of 0% to 20% = no therapeutic response, 
21% to 40% = slight TR, 41% to 60% = moderate TR, 61% Drug Design, Development and Therapy 2009:3 53
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to 80% = good TR, 81% to 100% = very good TR. In this 
study 89% showed a very good or good TR, 5.5% a moderate 
TR and 5.5% had no response. Headache, cheilitis, ﬂ  ush-
ing and conjunctivitis were reported. Two patients had to 
be reduced from 40 mg to 20 mg because of ﬂ  ushing and 
one because of conjunctivitis; after dose reduction their 
side effects disappeared. Unsatisfactory effect was seen in 
3 patients who received 20 mg daily, but after increasing 
dose to 40 mg daily, they all achieved a good response. The 
study suggested clinical effect on CHD and a manageable, 
dose-dependent proﬁ  le of common side effects.3
A randomized, double blind, placebo-controlled, 
multicenter trial was conducted in 2001/2002 in 43 clinics 
in Europe, enrolling 319 patients with CHD (hyperkeratotic 
eczema, ﬁ  ngertip eczema, dyshidrotic eczema). Patients 
were randomized into 4 blocks receiving treatment with 
placebo or with alitretinoin 10 mg, 20 mg or 40 mg once 
daily for 12 weeks. Twenty-four percent withdrew before 
completion, mainly caused by insufficient therapeutic 
response. The physician’s global assessment (PGA) was 
primarily used to measure the results of the treatment, and 
secondary efﬁ  cacy measures were the total lesion symptom 
score (TLSS) and patient’s global assessment (PaGA). 
PGA was classiﬁ  ed as severe/moderate/mild/almost clear 
or clear depending on the presence of erythema, scaling, 
hyperkeratosis/lichenification, vesiculation, edema, fis-
sures and pruritus/pain; the intensity of the symptom; and 
the proportion of the hand surface involved. The assess-
ment ‘clear’ was made in absence of all features, while the 
assessment of ‘severe’ required the following criteria to be 
met: at least one of the following to be moderate/severe: 
erythema, scaling, hyperkeratosis/licheniﬁ  cation; at least 
one severe of the following: vesiculation, edema, ﬁ  ssures, 
pain/pruritus; and more than 30% of the hand surface affected 
(see Ruzicka et al4,5 for additional detail). Responders 
according to PGA were 27%, 39%, and 41%, and 53% to 
placebo, at 10, 20 and 40 mg day, respectively. Patients were 
regarded as responders if they were rated as clear or almost 
clear at week 12. The closed Cochran-Armitage trend test 
used on the PGA results revealed a signiﬁ  cant and dose-
dependent effect (p  0.001%) The TLSS also showed a 
dose dependent reduction in symptoms with a −25, −59,−52 
and −70, 5 reduction, respectively (p  0.001, Jonckheere-
Terpstra trend test). Responders according to the PaGA 
were similar (12%, 29%, 34% and 43%) and according to 
the chi-squared test signiﬁ  cant at p = 0.01 for 10 mg/day, 
p = 0.002 for 20 mg/day and p  0.001 for 40 mg/day. During 
a 12-week follow-up among the responders 26% relapsed 
and required prescription therapy. Generally alitretinoin was 
well tolerated, but 53% of the 40 mg/d group experienced 
adverse events, most frequently headache, dry lips/mouth, 
ﬂ  ushing and erythema.4
Another multicenter trial was conducted in Europe and 
Canada with enrolment of 1032 patients from 2004 to 2006. 
Patients were randomized in the ratio 1:2:2 to placebo, 10 mg 
or 30 mg of oral alitretinoin once daily for up to 24 weeks. 
Dose reduction was not allowed. The primary efficacy 
parameter was PGA which was performed at screening and 
every 4 weeks during treatment. Response was deﬁ  ned as 
‘clear’ or ‘almost clear’. Response rates were clearly dose 
dependent with 195/409 (48%) responders in the 30 mg 
alitretinoin group, 115/418 (28%) in the 10 mg group and 
34/205 (17%) in the placebo group. Results of secondary 
efﬁ  cacy parameters were consistent with the primary. The 
time to response was found signiﬁ  cantly shorter in the 30 mg 
group compared to the 10 mg group. PaGA and median % 
reduction in mTLSS and median % reduction in extent of 
disease were all found signiﬁ  cantly more reduced in the 
30 mg group than in the placebo group. The most frequently 
adverse event was headache, leading to withdrawal of 4% 
of the patients in the 30 mg group and 1% of the patients in 
both the 10 mg group and the placebo group. The adverse 
events also comprised mucocutaneous events, hyperlipidemia 
and decreased thyroid stimulating hormone, all of these well 
known as retinoid class effects and, like headache, appeared 
to be dose dependent.5
The results of the studies are summarized in Table 1.
Use of alitretinoin 
in pre-malignancy and malignancy
Because retinoids have a normalizing effect on cell differen-
tiation, are anti-proliferative and regulate cell-apoptosis, they 
have shown some promise in the treatment of cancer.29–32
Treatment of former smokers
Lung cancer is one of the leading causes of cancer death, 
with tobacco smoking as a major risk factor. Lung cancer 
risk remains elevated after smoking cessation, and ways to 
stop cell differentiation and prevent carcinogenesis in former 
smokers have been investigated.
In former smokers the loss of retinoic acid receptor beta 
(RAR-β) expression in the bronchial epithelium is considered 
a biomarker of incipient neoplasia. To investigate the potential 
effect of retinoids in re-establishing the RAR-β expression, a 
randomized placebo controlled trial with 226 former smokers 
was conducted. Patients received either 9-cis-retinoic acid Drug Design, Development and Therapy 2009:3 54
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(RA) (100 mg), 13-cis-RA (1 mg/kg) plus α-tocopherol or 
placebo. The effect was evaluated trough bronchoscopy and 
biopsies from 6 different locations before and after treatment, 
and the specimens were evaluated for squamous metaplasia, 
dysplasia and RAR-β-expression. A total of 177 subjects 
completed at least 3 months of therapy and the examination 
3 months after; in these RAR-β-expression at baseline was 
found in 62.6%. A signiﬁ  cant increase in RAR-β was found in 
the 9-cis-RA group, in which 15 subjects changed from nega-
tive to positive expression and 5 from positive to negative 
expression. These changes were not found to be signiﬁ  cant 
in the other groups.
Metaplasia was found in 6.9% of all baseline samples 
and 29.6% of subjects. Dysplasia was found in 5 subjects. 
A signiﬁ  cant percentage decline in subjects with metaplasia 
was found in the 9-cis-RA group, but not in the others, and 
not when quantiﬁ  ed as a continuous variable (metaplasia 
index), where the total numbers of samples with metaplasia 
were evaluated. It was hypothesized that the restoration of 
RAR-β reﬂ  ects suppression of bronchial neoplasia.33
As described above the primary end-point was RAR-
β-expression, but later the group published an analysis of the 
anti-proliferative effect of the two retinoids trough expression 
of Ki-67. In the per-subject analyses treatment with 13-cis-RA 
plus α-tocopherol was statistically signiﬁ  cantly associated 
with a reduced cell-proliferation after 3 months, but treatment 
with 9-cis-RA was not. In the per-site analyses both groups 
showed a statistically signiﬁ  cant decreased proliferation 
assessed by the Ki-67 labeling index.34
Because low serum concentrations of antioxidants is sus-
pected to be associated with an increased risk of cancer, the 
same group conducted a retrospective analysis of the blood 
specimens taken before and after the treatment from the same 
randomized study, to determine whether 9-cis-RA could 
elevate the s-α-tocopherol in former smokers. The arm receiv-
ing 13-cis-RA plus α-tocopherol was excluded from this 
analysis. The baseline s-α-tocopherol in the 9-cis-RA group 
and the placebo group did not differ, but it was signiﬁ  cantly 
associated with serum triglyceride level and age.
Serum α-tocopherol signiﬁ  cantly increased over time in 
the 9-cis-RA group, but not in the placebo group.35
Kaposi’s sarcoma
Several studies have shown positive results with the treatment 
of KS with topical alitretinoin, as well as alitretinoin given 
orally. KS is a tumor caused by the human herpes virus 8 
(HHV 8) and it is often associated with acquired immune 
deﬁ  ciency syndrome (AIDS), but after the development of 
highly active antiretroviral therapy (HAART) the frequency 
of KS has declined.
In 1996–1997 the first randomized, double-blind, 
controlled, multicenter study of the safety and efﬁ  cacy 
of topical alitretinoin was conducted in the US, enrolling 
268 patients with AIDS and KS, with 134 patients receiving 
treatment with a topical alitretinoin gel 0.1% and 134 patients 
a vehicle gel. Patients had at least 6 lesions and applied the 
gel 3 times daily for the ﬁ  rst 2 weeks and 4 times daily for 
the last 10 weeks of the study period.
During the study the lesions were assessed for area, 
height, color and pain with responses evaluated and deﬁ  ned 
by ACTG-criteria (Aids Clinical Trial Group). In total 34% 
of patients receiving alitretinoin 0.1% gel achieved partial 
response (PR) and 0.7% complete response (CR), compared 
with 18% and 0%, respectively, in the group receiving vehicle 
gel. After the blinded part of the trial, patients were offered 
to continue treatment in an open label study, and 14 weeks 
of treatment with alitretinoin gel gave a 50% response rate 
and 27 weeks a 75% response rate.6
A further phase 1 and 2 dose escalation study enrolled 
115 AIDS patients with KS from 9 centers in an open-label 
study with alitretinoin gel. All patients received alitretinoin 
gel either 0.05% or 0.1% twice daily for the ﬁ  rst 2 weeks, 
following an escalation dose every second week, until 
the most intensive, tolerated dose was reached. In total 
Table 1 Summarized results of clinical studies of alitretinoin in chronic hand dermatitis indicating a response rate of 27% to 89% depending 
on dosage and duration of treatment
Patients Doses Duration Responders
Bollag and Ott3 38 Open-label 20–40 mg 2.3 months (mean)
89% (total) TLSS
Ruzicka et al4 319 Randomized 10–40 mg 12 weeks
39%–41%–53% (10–20–40 mg) PGA
Ruzicka et al5 1032 Randomized 10–30 mg –24 weeks 28%–48% (10–30 mg) PGA
Abbreviations: PGA, physician’s global assessment;   TLSS, total lesion symptom score.Drug Design, Development and Therapy 2009:3 55
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758 lesions were treated. The median time for treatment was 
14 weeks. In the group of treated lesions 27% of patients 
had response to treatment, compared to control lesions with 
response in 11%, according to the ACTG criteria.7
Two non-randomized studies evaluated the effect of 
systemic alitretinoin in the treatment of AIDS-related KS. 
These phase II trials treated 60 and 57 patients with up to 
140 mg/m2 escalating from 60 mg/m2, respectively. The 
median duration of therapy was 15 weeks in both trials, and 
the overall response rate was 37% and 39%, using the ACTG 
criteria. Twenty-eight and 21 (37%) patients withdrew from 
the study treatment because of adverse events (headache, 
skin toxicity, depression). Seven serious adverse events 
related to alitretinoin treatment were reported in 5 patients 
from one of the trials: pancreatitis, hypercalcinuria and mild 
renal insufﬁ  ciency, anemia and severe headache. Cholesterol 
and triglyceride elevation were seen, but it is important 
to remember that protease inhibitors can have the same 
effect. Skin toxicity was cumulative, and levels of plasma 
cholesterol increased over time.8,9
A further randomized controlled trail supported the 
superiority of alitretinoin over vehicle in the treatment of KS. 
The group included 134 patients receiving either alitretinoin 
gel 0.1% or a vehicle gel twice daily for 12 weeks. In the 
alitretinoin group, response was favorable with 37% respond-
ers versus only 7% responders in the vehicle gel group.10
Other malignancies
Hematological malignancies have previously been treated 
with retinoids. After 9-cis-RA has been introduced, its effect 
in hematology is under investigation.
A group of 29 patients with non-hodgkin and refractory 
T-cell lymphomas were treated with 9-cis-RA as a single 
daily oral dose of 100 mg/m2, escalating to 140 mg/m2 after 
2 weeks. One patient responded to treatment with complete 
remission, 3 patients had a partial response, 1 patient had a 
minor response, 9 patients were stable in disease, and 1 did 
not respond, but had progression in disease. Toxic effects 
resulted in discontinuation of treatment in 5 patients (head-
ache, fatigue, and hypercalcemia) and required dose reduc-
tion in 8 patients. One patient died before he started treatment. 
Toxic effects reported were: dry skin, headache, xerostoma, 
fatigue, nausea, peripheral edema, fever of unknown origin, 
infection, dry eyes and cheilitis.11
In the US 18 patients diagnosed with acute promyelocytic 
leukemia (APL) were treated with 9-cis-RA in the period 
1994–1996 in a non-randomized study. The patients received 
30 to 230 mg/m2 as a single oral dose in the trial. Five were 
newly diagnosed and 4 of these achieved complete remission for 
17 to 27 months. Thirteen patients were previously treated and 
4 of these achieved complete remission in 14 to 40 months.
Headache and dry skin were the most common adverse 
reactions reported by 76% and 59%, respectively.12
A multicenter phase II study included 30 patients with 
myelodysplatic syndromes, with 25 available for assessment. 
They received 60 mg/m2 daily in the ﬁ  rst week, escalating 
to 100 mg/m2 in the second week and 140 mg/m2 in the 
third week.
One patient achieved complete remission and 4 patients 
responded with reduced transfusion requirements, making the 
overall response rate 20%. Headache, dry skin, arthralgias and 
rashes were frequently reported adverse events in 77%, 57%, 
30% and 23% of the patients, respectively. Hyperlipidemi and 
hypercalcemia were affected, supporting other observations 
of alitretinoin and retinoids in general.13
A group of 112 patients with cervical intraepithelial 
neoplasia 2/3 (CIN 2/3) received a daily dose of 25 or 50 mg 
of alitretinoin or placebo. There were no signiﬁ  cant differ-
ences in regression among the 3 groups. Headache, fatigue and 
nausea were the most frequent reported adverse events.14
Another 41 patients with advanced cancer and previous 
failure to standard therapy were included in a safety study 
of alitretinoin and additionally the effect was evaluated, but 
no tumor responses were observed.15
Discussion
Hand eczema is a signiﬁ  cant health problem which occurs 
both in association with underlying skin disease, eg, atopic 
eczema, as well as independently.36 There is a great need for 
new treatment options for intractable hand eczema, because 
it is a frequent and invalidating disease in the population. 
Recent advances in topical treatment have suggested that 
TCIs may be effective in mild-to-moderate CHD.17,18 The 
disadvantage of TCIs is their incompatibility with UV light 
irradiation and therapy, because of the potentially increased 
risk of non-melanoma skin cancer associated with this treat-
ment. Topical retinoids have, however, also shown promise 
when good results appeared in a study of topically treatment 
of CHD with bexarotene gel.27
When topical treatments fail to control CHD, systemic 
immunosuppression is a possibility. Because of the side effects 
a non-immunosuppressive effective therapy is preferable, and 
acitretin has hitherto been the favored option for this. Acitretin 
is a retinoid that targets and activates RAR-receptors. In 
contrast, alitretinoin is a pan-retinoid-receptor agonist and 
therefore has a different target proﬁ  le. Trials with alitretinoin Drug Design, Development and Therapy 2009:3 56
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(9-cis-RA) in the treatment of CHD have given promising 
results.3–5 Patients were treated with doses from 10 to 40 mg 
daily and response was assessed according to PGA. When 
alitretinoin dose was taking into account, 28% to 53% of 
patients responded, with clearl dose dependency. In one study 
a durable remission was induced with a median of 5.5 to 6.2 
months before responding patients relapsed with 75% of their 
initial symptoms, another found 26% of responders having a 
relapse during a 12-week follow up.4,5
Because a retinoid has a normalizing effect on cell 
differentiation, proliferation and apoptosis, it has also been 
proposed as a treatment in neoplastic diseases. Several 
studies have been carried out with alitretinoin topically and 
systemically in the treatment of AIDS related KS. Respone 
rates from 27% to 39% were reported for a treatment period 
up to 15 weeks.6–10 As a systemic treatment, the adverse 
events limits its use in these patients, and in some patients 
the widespread affection of the skin, makes the topically 
treatment impractical. As a therapy in other malignant 
diseases the good results have been few.11–15
The most frequently reported adverse events were 
headache, dry lips/mouth, ﬂ  ushing, erythema, hyperlipidemia 
and decreased thyroid-stimulating hormone and seemed to 
be dose dependent. Headache remained the primary dose-
limiting adverse event, when alitretinoin was given at much 
higher doses as anti-cancer therapy.
In conclusion the results of published studies on 
alitretinoin suggests that the drug has a considerable 
therapeutic potential, with a good safety proﬁ  le, for patients 
with severe hand eczema not responding to conventional 
topical therapy, whereas it has not been equally convincing 
as a potential anti-neoplastic agent, except for the treatment 
of Kaposi’s sarcoma.
Additional relevant studies however need to be done to 
establish the full potential of this drug. Notably the potential 
for tachyphylaxis remains to be explored, as does the direct 
clinical comparison with known retinoids such as acitretin, 
which have also shown some potential in the treatment of 
CHD and skin cancer.
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